The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials-Reference-Cited by-同舟云学术

The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials

Published:2021-06-04 Issue:1 Volume:189 Page:111-120
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Ortega Expósito Carlos^ORCID,Falo Catalina,Pernas Sonia,Pérez Carton Samuel,Gil Gil Miguel,Ortega Raul,Pérez Montero Héctor,Stradella Agostina,Martinez Evelyn,Laplana Maria,Salinas Sira,Luzardo Ana,Soler Teresa,Fernández Montoli Maria Eulalia,Azcarate Juan,Guma Anna,Petit Anna,Benitez Ana,Bajen Maite,Reyes Junca Jose G.,Campos Miriam,Ruiz Raquel,Ponce Jordi,Pla Maria J.,García Tejedor Amparo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06274-9.pdf

Reference25 articles.

1. de Boniface J et al (2017) Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: The randomized controlled SENOMAC trial. BMC Cancer 17(1):1–7. https://doi.org/10.1186/s12885-017-3361-y

2. Giuliano AE et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918–926. https://doi.org/10.1001/jama.2017.11470

3. Donker M et al (2015) AMAROS trial. Lancet Oncol 15(12):1303–1310. https://doi.org/10.1016/S1470-2045(14)70460-7.Radiotherapy

4. Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M (2017) The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol 24(12):3527–3533. https://doi.org/10.1245/s10434-017-6016-y

5. Verheuvel NC, Voogd AC, Tjan-Heijnen VCG, Roumen RMH (2016) Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients. Eur J Surg Oncol 42(8):1162–1168. https://doi.org/10.1016/j.ejso.2016.05.007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with ≥ 3 positive sentinel lymph nodes based on machine-learning algorithms;BMC Cancer;2024-09-02

2. Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases;Clinical Breast Cancer;2024-06

3. Axillary Surgery for Breast Cancer in 2024;Cancers;2024-04-23

4. Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy;Annals of Surgical Oncology;2024-02-17

5. Axillary management in patients with clinical node-negative early breast cancer and positive sentinel lymph node: a systematic review and meta-analysis;Frontiers in Oncology;2024-01-08